From condemning the Jan. 6 Capitol riots to helping fund the President-elect’s impending inauguration, recent years have seen ...

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Shares ...

The U.S. continues to charge significantly higher prices for prescription drugs compared with similarly wealthy countries.

The board of Pfizer Inc. ( NYSE:PFE ) has announced that it will be paying its dividend of $0.43 on the 7th of ...

At the same time, the expiration of key patents is coming up for some major Pfizer drugs, including blood thinner Eliquis and ...

A patient-led study examines the potential of extended Paxlovid courses for Long COVID relief, documenting varied outcomes ...

PFE's strong economic moat is threatened by upcoming patent expirations, but its oncology segment shows promising growth ...

Sangamo, a gene therapy pioneer, loses a financial lifeline as Pfizer drops a gene therapy program for hemophilia.

Pfizer gave Sangamo Therapeutics coal for Christmas, terminating a hemophilia A gene therapy pact to deprive the ...

PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, today announced an expansion of their partnership with Pfizer. The parties will launch a new Antibody- ...

The pharmaceutical industry can be a tough business. Companies must innovate constantly to stay relevant because patents ...

Pfizer plans to achieve $4 billion in savings, invest in key areas like oncology and vaccines, and project double-digit EPS ...